The role of vitamin D in cardiovascular disease: From present evidence to future perspectives

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 253-263

  Brandenburg, Vincent M ^a   Vervloet, Marc G ^b   Marx, Nikolaus ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arterial hypertension; Calcidiol; Cardiovascular disease; Cardiovascular risk; Phosphate; Vitamin d

Indexed keywords

ALFACALCIDOL; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE; RETINOID X RECEPTOR; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ARTERIAL STIFFNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MORTALITY; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DRUG OVERDOSE; HUMANS; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84869493869     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.005     Document Type: Review

References (105)

1. Bouillon R., Carmeliet G., Verlinden L., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008, 29(6):726-776.
2. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984, 74(6):2136-2143.
3. Wolf M., Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 2007, 103(3-5):487-490.
4. Krause R., Schober-Halstenberg H.J., Edenharter G., Haas K., Roth H.J., Frei U. Vitamin D status and mortality of German hemodialysis patients. Anticancer Res 2012, 32(1):391-395.
5. Pecovnik-Balon B., Jakopin E., Bevc S., Knehtl M., Gorenjak M. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial 2009, 13(4):268-272.
6. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72(8):1004-1013.
7. Souberbielle J.C., Body J.J., Lappe J.M., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010, 9(11):709-715.
8. Anderson J.L., May H.T., Horne B.D., et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010, 106(7):963-968.
9. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol 1981, 10(4):337-341.
10. Pilz S., Tomaschitz A., Marz W., et al. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2011, 75(5):575-584.
11. Liss Y., Frishman W.H. Vitamin D: a cardioprotective agent?. Cardiol Rev 2012, 20(1):38-44.
12. Van der Schueren B.J., Verstuyf A., Mathieu C. Straight from D-Heart: vitamin D status and cardiovascular disease. Curr Opin Lipidol 2012, 23(1):17-23.
13. Lavie C.J., Lee J.H., Milani R.V. Vitamin D and cardiovascular disease will it live up to its hype?. J Am Coll Cardiol 2011, 58(15):1547-1556.
14. Cozzolini M., Bover J., Vervloet M., Brandenburg V. A multidisciplinary review of the science of vitamin D receptor activation. Kidney Int 2011, 1(4):107-110.
15. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
16. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80(6 Suppl.):1689S-1696S.
17. Dusso A.S., Finch J., Brown A., et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991, 72(1):157-164.
18. Safadi F.F., Thornton P., Magiera H., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999, 103(2):239-251.
19. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96(4):507-515.
20. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011, 25(4):543-559.
21. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010, 61:91-104.
22. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009, 75(11):1166-1172.
23. Prie D., Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/klotho system. Clin J Am Soc Nephrol 2010, 5(9):1717-1722.
24. Kuro O. Phosphate and klotho. Kidney Int 2011, (Suppl. 121):S20-S23.
25. Isakova T., Wahl P., Vargas G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79(12):1370-1378.
26. Vervloet M.G., van Ittersum F.J., Buttler R.M., Heijboer A.C., Blankenstein M.A., ter Wee P.M. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011, 6(2):383-389.
27. Gutierrez O.M., Wolf M., Taylor E.N. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011, 6(12):2871-2878.
28. Finch J.L., Tokumoto M., Nakamura H., et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Ren Physiol 2010, 298(6):F1315-F1322.
29. Hansen D., Rasmussen K., Pedersen S.M., Rasmussen L.M., Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012, 27(6):2263-2269.
30. Fraga C., Blanco M., Vigo E., Segura C., Garcia-Caballero T., Perez-Fernandez R. Ontogenesis of the vitamin D receptor in rat heart. Histochem Cell Biol 2002, 117(6):547-550.
31. de Borst M.H., Vervloet M.G., ter Wee P.M., Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011, 22(9):1603-1609.
32. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110(2):229-238.
33. Kong J., Li Y.C. Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol 2003, 285(1):R255-R261.
34. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288(1):E125-E132.
35. Chen S., Law C.S., Grigsby C.L., et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011, 124(17):1838-1847.
36. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008, 74(2):170-179.
37. Bodyak N., Ayus J.C., Achinger S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007, 104(43):16810-16815.
38. Price P.A., Faus S.A., Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000, 20(2):317-327.
39. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001, 21(10):1610-1616.
40. Price P.A., Buckley J.R., Williamson M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 2001, 131(11):2910-2915.
41. Lopez I., Mendoza F.J., Aguilera-Tejero E., et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008, 73(3):300-307.
42. Mizobuchi M., Ogata H., Koiwa F., Kinugasa E., Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone 2009, 45(Suppl. 1):S26-S29.
43. St Arnaud R., Arabian A., Travers R., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000, 141(7):2658-2666.
44. Bernheim J., Benchetrit S. The potential roles of FGF23 and klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011, 26(8):2433-2438.
45. Stubbs J.R., Liu S., Tang W., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007, 18(7):2116-2124.
46. Bjelakovic G., Gluud L.L., Nikolova D., et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011, (7). CD007470.
47. Ellam T.J., Chico T.J. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012, 220(2):310-318.
48. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109(6):697-711.
49. Lau W.L., Pai A., Moe S.M., Giachelli C.M. Direct effects of phosphate on vascular cell function. Adv Chron Kidney Dis 2011, 18(2):105-112.
50. Lau W.L., Festing M.H., Giachelli C.M. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 2010, 104(3):464-470.
51. Ritz E., Hahn K., Ketteler M., Kuhlmann M.K., Mann J. Phosphate additives in food - a health risk. Dtsch Arztebl Int 2012, 109(4):49-55.
52. Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009, 20(2):397-404.
53. Dhingra R., Sullivan L.M., Fox C.S., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167(9):879-885.
54. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359(6):584-592.
55. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med 2010, 152(10):640-648.
56. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
57. Hesse M., Frohlich L.F., Zeitz U., Lanske B., Erben R.G. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007, 26(2):75-84.
58. Sitara D., Kim S., Razzaque M.S., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4(8):e1000154.
59. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009, 20(8):1805-1812.
60. Wolf M., Shah A., Gutierrez O., Ankers E., Monroy M., Tamez H., Steele D., Chang Y., Camargo C.A., Tonelli M., Thadhani R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72(8):1004-1013.
61. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338(12):777-783.
62. Priemel M., von Domarus C., Klatte T.O., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010, 25(2):305-312.
63. Rosen C.J. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011, 364(3):248-254.
64. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16(7):713-716.
65. Dawson-Hughes B. What is the optimal dietary intake of vitamin D for reducing fracture risk?. Calcif Tissue Int 2012, [Epub ahead of print].
66. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367(1):40-49.
67. Heaney R.P., Armas L.A., Shary J.R., Bell N.H., Binkley N., Hollis B.W. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008, 87(6):1738-1742.
68. Drechsler C., Pilz S., Obermayer-Pietsch B., et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010, 31(18):2253-2261.
69. Zhao G., Ford E.S., Li C., Croft J.B. Serum 25-hydroxyvitamin D levels and all-cause and cardiovascular disease mortality among US adults with hypertension: the NHANES linked mortality study. J Hypertens 2012, 30(2):284-289.
70. Melamed M.L., Michos E.D., Post W., Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168(15):1629-1637.
71. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
72. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354(15):1567-1577.
73. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354(15):1578-1588.
74. Reid D., Toole B.J., Knox S., et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 2011, 93(5):1006-1011.
75. London G.M., Guerin A.P., Verbeke F.H., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007, 18(2):613-620.
76. Chitalia N., Recio-Mayoral A., Kaski J.C., Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis 2012, 220(1):265-268.
77. Harris R.A., Pedersen-White J., Guo D.H., et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens 2011, 24(5):557-562.
78. Longenecker C.T., Hileman C.O., Carman T.L., et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther 2012, 17(4):613-621.
79. Tarcin O., Yavuz D.G., Ozben B., et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009, 94(10):4023-4030.
80. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008, 25(3):320-325.
81. Dong Y., Stallmann-Jorgensen I.S., Pollock N.K., et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010, 95(10):4584-4591.
82. Burgaz A., Orsini N., Larsson S.C., Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011, 29(4):636-645.
83. Scragg R., Wishart J., Stewart A., et al. No effect of ultraviolet radiation on blood pressure and other cardiovascular risk factors. J Hypertens 2011, 29(9):1749-1756.
84. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet 1998, 352(9129):709-710.
85. Hsia J., Heiss G., Ren H., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115(7):846-854.
86. Bischoff-Ferrari H.A., Dawson-Hughes B., Stocklin E., et al. Oral supplementation with 25(OH)D(3) versus vitamin D(3): effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone and Miner Res 2012, 27(1):160-169.
87. Norman A.W., Frankel J.B., Heldt A.M., Grodsky G.M. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209(4458):823-825.
88. Mitri J., Muraru M.D., Pittas A.G. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011, 65(9):1005-1015.
89. Pittas A.G., Nelson J., Mitri J., et al. Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the diabetes prevention Program. Diabetes Care 2012, 35(3):565-573.
90. Thrailkill K.M., Jo C.H., Cockrell G.E., Moreau C.S., Fowlkes J.L. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?. J Clin Endocrinol Metab 2011, 96(1):142-149.
91. Doorenbos C.R., de Cuba M.M., Vogt L., et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol 2012, 128(1-2):56-61.
92. Mitri J., Dawson-Hughes B., Hu F.B., Pittas A.G. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the calcium and vitamin D for diabetes mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 2011, 94(2):486-494.
93. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in south Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2010, 103(4):549-555.
94. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376(9752):1543-1551.
95. Testa A., Mallamaci F., Benedetto F.A., et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010, 25(2):313-319.
96. Wilke R.A., Simpson R.U., Mukesh B.N., et al. Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension. Pharmacogenomics 2009, 10(11):1789-1797.
97. Thadhani R., Appelbaum E., Pritchett Y., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. J Am Med Assoc 2012, 307(7):674-684.
98. Patel D.A., Lavie C.J., Milani R.V., Ventura H.O. Left atrial volume index predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction. Mayo Clin Proc 2011, 86(8):730-737.
99. Manson J.E., Allison M.A., Carr J.J., et al. Calcium/vitamin D supplementation and coronary artery calcification in the women's health initiative. Menopause 2010, 17(4):683-691.
100. Bolland M.J., Grey A., Avenell A., Gamble G.D., Reid I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the women's health initiative limited access dataset and meta-analysis. BMJ 2011, 342:d2040.
101. Wang L., Manson J.E., Sesso H.D. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs 2012, 12(2):105-116.
102. LaCroix A.Z., Kotchen J., Anderson G., et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the women's health initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009, 64(5):559-567.
103. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167(16):1730-1737.
104. Elamin M.B., Abu Elnour N.O., Elamin K.B., et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96(7):1931-1942.
105. Bolland M.J., Grey A., Reid I.R. Vitamin D and falls. Time for a moratorium on vitamin D meta-analyses?. BMJ 2009, 339:b4394.